Compare AUID & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AUID | PASG |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | United States | United States |
| Employees | N/A | 27 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.2M | 26.0M |
| IPO Year | 2014 | 2020 |
| Metric | AUID | PASG |
|---|---|---|
| Price | $1.36 | $7.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $23.50 |
| AVG Volume (30 Days) | ★ 257.5K | 31.7K |
| Earning Date | 05-12-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $886,485.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 365.86 | N/A |
| 52 Week Low | $0.84 | $0.28 |
| 52 Week High | $9.44 | $20.00 |
| Indicator | AUID | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 41.27 | 38.17 |
| Support Level | $1.19 | $6.71 |
| Resistance Level | $1.38 | $7.72 |
| Average True Range (ATR) | 0.11 | 0.70 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 5.59 | 18.83 |
AuthID Inc is a company engaged in ensuring cyber-savvy enterprises Know Who's Behind the Device, for every customer or employee login and transaction. Through its easy-to-integrate, patented, biometric identity platform, authID quickly and accurately verifies a user's identity, eliminating any assumption of who is behind a device and preventing cybercriminals from taking over accounts. authID combines digital onboarding, biometric password less authentication and account recovery, with a fast, accurate, user-friendly experience-delivering identity verification.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.